SCHEMBL25376374

SCHEMBL25376374

CC(NC(C)c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
ALDH1A1 P00352 4/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
KMT2A Q03164 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.42
ADRB2 P07550 1/20 0.42
MAPKAPK2 P49137 1/20 0.41
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14180861 0.91 NPC1 (0.56) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL12154083 0.91 NPC1 (0.56) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL12154078 0.91 NPC1 (0.56) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL14180860 0.91 NPC1 (0.56) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL14561176 0.90 HTT (0.46) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL10315763 0.90 HTT (0.46) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL10087171 0.90 HTT (0.46) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL19954265 0.83 HTT (0.45) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL14457207 0.83 HTT (0.41) HTTALDH1A1KDM4ENPC1KMT2A
SCHEMBL19286209 0.82 HTT (0.47) HTTALDH1A1KDM4ENPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 HTT 1100/4885ALDH1A1 29/4885KDM4E 1639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.